Name | Sorafenib |
---|---|
Supplier | Cell Signaling Technology |
Catalog | 8705 |
Prices | $109.00 |
Sizes | 10 mg |
Formula | C21H16ClF3N4O3•C7H8O3S |
Molecular Weight | 637.03 g/mol |
Purity | >99% |
Description | Sorafenib, also known as Bay 43-9006, is a novel multikinase inhibitor that targets the RAF family of serine/threonine kinases and tyrosine kinase receptors involved in tumor progression and tumor angiogenesis, including: VEGFR-2 (IC 50 = 90 nM), VEGFR-3 (IC 50 = 20 nM), PDGFR- (IC 50 = 57 nM), c-KIT (IC 50 = 68 nM), and Flt3 (IC 50 = 58 nM) (1). Research studies have demonstrated that sorafenib induces apoptosis in several tumor cell lines through the down-regulation of the antiapoptotic protein myeloid cell leukemia-1 (Mcl-1). Down-regulation of Mcl-1 by sorafenib is associated with the release of cytochrome c from mitochondria into the cytosol and caspase activation, leading to apoptotic cell death (2). STAT3 inhibition by sorafenib has been observed in multiple cell types (3-5). |
Supplier Page | Shop |